Trilaciclib hydrochloride NEW
| Price | $30 | $85 | $155 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: Trilaciclib hydrochloride | CAS No.: 1977495-97-8 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | Trilaciclib hydrochloride |
| Description | Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6). |
| In vitro | Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1 arrest. A transient Trilaciclib hydrochloride-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression. |
| In vivo | G1T28 inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest.n vivo, G1T28 reversibly and in a dose-dependent manner, regulates the proliferation of HSPCs.Pretreatment of mice with oral G1T28 allows for the faster recovery of CBCs following chemotherapy treatment.Likewise, oral G1T28 does not protect RB-deficient tumors from chemotherapy but adds to the antitumor effect.Although this effect was found in athymic mice that lack T lymphocytes, it is still possible that the enhanced efficacy is due to preservation of other immune cell types such as natural killer cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Insoluble H2O : 3.9 mg/mL (7.51 mM), Sonication is recommended. |
| Keywords | Trilaciclib hydrochloride | Trilaciclib | Inhibitor | inhibit | G1T28 Hydrochloride | G1T28 | Cyclin dependent kinase | CDK6/CyclinD3 | cdk6/cyclin D3 | Cdk4/cyclin D1 | CDK4/Cyc D1 | CDK |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $1.50 |
VIP5Y
|
Shaanxi Didu New Materials Co. Ltd
|
2026-05-15 | |
| $30.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | |
|
VIP5Y
|
Shanghai Joiny Pharmaceutical Co.,LTD
|
2025-12-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY